U. Moll

U. Moll, F. Valea, J. Chumas, 1997, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells

F. Talos, U. Moll, Victoria Fischer, 2011, Molecular Cancer Research.

Cancer Genes and Genomics Functional Inactivation of Endogenous MDM 2 and CHIP by HSP 90 Causes Aberrant Stabilization of Mutant p 53 in Human Cancer Cells

F. Talos, U. Moll, Victoria Fischer, 2011 .

HSP90 inhibitor antagonizing MIF

U. Moll, M. Dobbelstein, R. Schulz, 2012, Oncoimmunology.

p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo

U. Moll, N. Marchenko, Safia A Mirza, 2017, Cell Death & Disease.

The neuroendocrine thymus

U. Moll, V. Geenen, J. Legros, 1988, Histochemistry.

The post-translational phosphorylation and acetylation modification profile is not the determining factor in targeting endogenous stress-induced p53 to mitochondria

U. Moll, S. Erster, A. Nemajerova, 2005, Cell Death and Differentiation.

Functional histology of the neuroendocrine thymus

U. Moll, 1997, Microscopy research and technique.

Colloidal gold-labeled insulin complex

U. Moll, E. Pfeiffer, C. Thun, 2004, Histochemistry.

Single-cell genomic analysis of triple-negative breast cancer fibroblasts uncovers evolutionarily conserved features and potential therapeutic targets

S. Powers, Jonathan Preall, U. Moll, 2022, bioRxiv.

Aristolochic acid and the etiology of endemic (Balkan) nephropathy

B. Jelaković, U. Moll, N. Slade, 2007, Proceedings of the National Academy of Sciences.

Transcription-independent pro-apoptotic functions of p53.

W. Deppert, U. Moll, Sonja Wolff, 2005, Current opinion in cell biology.

Extraction of type IV collagenase/gelatinase from plasma membranes of human pancreatic cancer cells.

L. Liotta, U. Moll, S. Zucker, 1992, Matrix (Stuttgart, Germany). Supplement.

p53, p63 and p73--solos, alliances and feuds among family members.

U. Moll, S. Erster, A. Zaika, 2001, Biochimica et biophysica acta.

Macrophage migration inhibitory factor protects from nonmelanoma epidermal tumors by regulating the number of antigen‐presenting cells in skin

M. Dewor, R. Bucala, M. Hallek, 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Spinal metastasis of a thyroglobulin-rich Hürthle cell carcinoma detected by fine needle aspiration. Light and electron microscopic study of an unusual case.

U. Moll, A. Heimann, 1989, Acta cytologica.

Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes

R A Knight, G Melino, G M Cohen, 2009, Cell Death and Differentiation.

Mitochondrial death functions of p53

U. Moll, N. Marchenko, 2014, Molecular & cellular oncology.

The MDM2-p53 interaction.

U. Moll, O. Petrenko, Ute M Moll, 2003, Molecular cancer research : MCR.

Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors.

U. Moll, G. Riou, G. Riou, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018

S. Lipton, A. Ciechanover, T. Luedde, 2018, Cell Death & Differentiation.

Regulation of autophagy by cytoplasmic p53

Nektarios Tavernarakis, Chrysanthi Samara, Paolo Pinton, 2008, Nature Cell Biology.

Rational design of DNA sequences for nanotechnology, microarrays and molecular computers using Eulerian graphs.

Zdenek Moravek, Petr Pancoska, U. Moll, 2004, Nucleic acids research.

Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.

F. Greten, U. Moll, M. Dobbelstein, 2018, Cancer cell.

p 53-Responsive MicroRNAs 192 and 215 Are Capable of Inducing Cell Cycle Arrest

T. Ørntoft, C. Andersen, U. Moll, 2008 .

Stress-mediated nuclear stabilization of p53 is regulated by ubiquitination and importin-α3 binding

N. Reich, U. Moll, N. Marchenko, 2010, Cell Death and Differentiation.

p53 Opens the Mitochondrial Permeability Transition Pore to Trigger Necrosis in Response to Oxidative Damage

U. Moll, Katharina Zirngibl, 2014 .

p53's mitochondrial translocation and MOMP action is independent of Puma and Bax and severely disrupts mitochondrial membrane integrity

U. Moll, S. Erster, Sonja Wolff, 2008, Cell Research.

Classical and novel roles of p 53 and prospects for anticancer therapy

U. Moll, V. Andrés, S. Sanz-González, 2008 .

Classic and novel roles of p53: prospects for anticancer therapy.

U. Moll, V. Andrés, S. Sanz-González, 2007, Trends in molecular medicine.

The MDM 2p 53 Interaction

U. Moll, O. Petrenko, Ute M. Moll, 2003 .

A Novel In Vitro CypD-Mediated p53 Aggregation Assay Suggests a Model for Mitochondrial Permeability Transition by Chaperone Systems.

Michael Tong, M. Seeliger, U. Moll, 2016, Journal of molecular biology.

Cajal‐Retzius neurons are required for the development of the human hippocampal fissure

G. Meyer, U. Moll, A. Nemajerova, 2019, Journal of anatomy.

MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53.

G. Lozano, U. Moll, Yanping Zhang, 2016, Molecular cell.

ΔNp63 regulates select routes of reprogramming via multiple mechanisms

S. Sinha, U. Moll, O. Petrenko, 2013, Cell Death and Differentiation.

Generation of p53-deficient induced pluripotent stem cells from mouse embryo fibroblasts.

U. Moll, E. Alexandrova, 2013, Methods in molecular biology.

Two-factor reprogramming of somatic cells to pluripotent stem cells reveals partial functional redundancy of Sox2 and Klf4

U. Moll, O. Petrenko, A. Nemajerova, 2012, Cell Death and Differentiation.

Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosity

U. Moll, Jinyu Li, A. Neesse, 2021, Nature Communications.

Suppression of HSF1 activity by wildtype p53 creates the driving force for p53 loss-of-heterozygosity, enabling mutant p53 stabilization and invasion

U. Moll, Jinyu Li, Nadine Stark, 2020, bioRxiv.

L. Donehower, A. Langerød, L. Strong, 2017, Cancer research.

Direct reprogramming by oncogenic Ras and Myc

U. Moll, O. Petrenko, A. Nemajerova, 2013, Proceedings of the National Academy of Sciences.

Links between mutant p53 and genomic instability

U. Moll, Ute M. Moll, W. Hanel, 2012, Journal of cellular biochemistry.

Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion.

A. Levine, U. Moll, G. Riou, 1992, Proceedings of the National Academy of Sciences of the United States of America.

p63 and p73: roles in development and tumor formation.

U. Moll, N. Slade, 2004, Molecular cancer research : MCR.

Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells

U. Moll, M. Dobbelstein, D. Kramer, 2016, Cell Death and Differentiation.

TAp73 is essential for germ cell adhesion and maturation in testis

U. Moll, M. Dobbelstein, D. Kramer, 2014, The Journal of cell biology.

Efﬁcient RNA interference depends on global context of the target sequence: quantitative analysis of silencing efﬁciency using Eulerian graph representation of siRNA

Zdenek Moravek, Petr Pancoska, U. Moll, 2022 .

BclxL Changes Conformation upon Binding to Wild-type but Not Mutant p53 DNA Binding Domain*

C. Klein, H. Kessler, U. Moll, 2009, The Journal of Biological Chemistry.

Overexpression of the wild type p73 gene in breast cancer tissues and cell lines.

U. Moll, A. Zaika, N. Marchenko, 1999, Cancer research.

Role of the p53 family in stabilizing the genome and preventing polyploidization.

F. Talos, U. Moll, Flaminia Talos, 2010, Advances in experimental medicine and biology.

Monoubiquitylation promotes mitochondrial p53 translocation

U. Moll, S. Erster, N. Marchenko, 2007, The EMBO journal.

Mitochondrially targeted wild-type p53 suppresses growth of mutant p53 lymphomas in vivo

U. Moll, G. Palacios, 2006, Oncogene.

Clinical Relevance of Dominant-Negative p73 Isoforms for Responsiveness to Chemotherapy and Survival in Ovarian Cancer: Evidence for a Crucial p53-p73 Cross-talk In vivo

D. Tong, R. Zeillinger, U. Moll, 2005, Clinical Cancer Research.

Uterine papillary serous carcinoma evolves via a p53-driven pathway.

U. Moll, E. Chalas, J. Chumas, 1996, Human pathology.

Non-oncogenic roles of TAp73: from multiciliogenesis to metabolism

I. Amelio, G. Melino, V. Dötsch, 2017, Cell Death and Differentiation.

p53 in Human Cancer — Somatic and Inherited Mutations and Mutation-independent Mechanisms

U. Moll, N. Concin, 2005 .

Analysis of nuclear and cytoplasmic degradation of p53 in cells after stress.

U. Moll, T. Joseph, 2003, Methods in molecular biology.

Nuclear degradation of p53 occurs during down‐regulation of the p53 response after DNA damage

U. Moll, A. Zaika, Troy R. Shirangi, 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Transdominant ΔTAp73 Isoforms Are Frequently Up-regulated in Ovarian Cancer. Evidence for Their Role as Epigenetic p53 Inhibitors in Vivo

R. Zeillinger, H. Ulmer, U. Moll, 2004, Cancer Research.

p73 protein regulates DNA damage repair

W. El-Rifai, U. Moll, A. Zaika, 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Patterns of p73 N-terminal isoform expression and p53 status have prognostic value in gynecological cancers.

Petr Pancoska, U. Moll, N. Concin, 2006, International journal of oncology.

The Role of p53 and p73 Genes in Tumor Formation

U. Moll, N. Slade, 2005 .

The Biology Behind The Role of p 63 and p 73 in Tumor Formation and Progression : Coming of Age Toward Clinical Usefulness

U. Moll, 2003 .

ΔNp73, A Dominant-Negative Inhibitor of Wild-type p53 and TAp73, Is Up-regulated in Human Tumors

U. Moll, S. Erster, A. Zaika, 2002, The Journal of experimental medicine.

Oncogenes Induce and Activate Endogenous p73 Protein*

U. Moll, A. Zaika, C. Sansome, 2001, The Journal of Biological Chemistry.

Nuclear and mitochondrial apoptotic pathways of p53

U. Moll, A. Zaika, 2001, FEBS letters.

The prolyl-isomerase Pin1 activates the mitochondrial death program of p53

U. Moll, G. Del Sal, G. Sal, 2012, Cell Death and Differentiation.

In Vivo Mitochondrial p53 Translocation Triggers a Rapid First Wave of Cell Death in Response to DNA Damage That Can Precede p53 Target Gene Activation

U. Moll, M. Mihara, S. Erster, 2004, Molecular and Cellular Biology.

p53 and Nur77/TR3 – transcription factors that directly target mitochondria for cell death induction

U. Moll, N. Marchenko, X-k Zhang, 2006, Oncogene.

OVARIAN CARCINOMA ARISING IN ATYPICAL ENDOMETRIOSIS

U. Moll, E. Chalas, W. Mann, 1990, Obstetrics and gynecology.

HSP90-Stabilized MIF in Oncogenesis and Cell Growth Control

U. Moll, Ramona Schulz-Heddergott, 2017 .

Impaired DNA damage checkpoint response in MIF‐deficient mice

G. Fingerle-Rowson, U. Moll, O. Petrenko, 2007, The EMBO journal.

MIF loss impairs Myc-induced lymphomagenesis

G. Fingerle-Rowson, F. Talos, U. Moll, 2005, Cell Death and Differentiation.

Macrophage migration inhibitory factor MIF interferes with the Rb-E2F pathway.

U. Moll, O. Petrenko, 2005, Molecular cell.

Hyperubiquitylation of wild-type p53 contributes to cytoplasmic sequestration in neuroblastoma

U. Moll, N. Marchenko, M. Maurice, 2007, Cell Death and Differentiation.

Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium

I. Vergote, H. Ulmer, I. Ray-Coquard, 2019, Front. Oncol..

Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines.

S. Swendeman, U. Moll, N. Marchenko, 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

ΔNp73 stabilises TAp73 proteins but compromises their function due to inhibitory hetero-oligomer formation

U. Moll, S. Erster, A. Zaika, 2004, Cell Death and Differentiation.

The mitochondrial p53 pathway.

U. Moll, A. Vaseva, Ute M Moll, 2009, Biochimica et biophysica acta.

The mitochondrial p 53 pathway

U. Moll, A. Vaseva, 2009 .

Mitochondrially targeted wild-type p53 induces apoptosis in a solid human tumor xenograft model

U. Moll, A. Vaseva, H. Crawford, 2008, Cell cycle.

TAp73 is a central transcriptional regulator of airway multiciliogenesis

D. Schild, S. Bonn, U. Moll, 2016, Genes & development.

Loss of p73 promotes dissemination of Myc-induced B cell lymphomas in mice.

L. Trümper, U. Moll, O. Petrenko, 2010, The Journal of clinical investigation.

Ganetespib synergizes with cyclophosphamide to improve survival of mice with autochthonous tumors in a mutant p53-dependent manner

U. Moll, Sulan Xu, E. Alexandrova, 2017, Cell Death & Disease.

p73 is an essential regulator of neural stem cell maintenance in embryonal and adult CNS neurogenesis

W. Brück, F. Talos, U. Moll, 2010, Cell Death and Differentiation.

Role of p53 family members p73 and p63 in human hematological malignancies

U. Moll, E. Alexandrova, 2012, Leukemia & lymphoma.

Deregulated expression of ΔNp73α causes early embryonic lethality

U. Moll, S. Erster, G. Palacios, 2006, Cell Death and Differentiation.

DeltaN-p73alpha accumulates in human neuroblastic tumors.

M. Kaghad, D. Caput, U. Moll, 2002, The American journal of pathology.

Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer.

Dario Cattaneo, Eleonora Marrazzo, Massimo Broggini, 2008, European journal of cancer.

Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage

U. Moll, G. Zambetti, A. Ostermeyer, 1996, Molecular and cellular biology.

Mitochondrial p53 mediates a transcription-independent regulation of cell respiration and interacts with the mitochondrial F₁F₀-ATP synthase

U. Moll, B. Mignotte, J. Vayssière, 2013, Cell cycle.

The transcription-independent mitochondrial p53 program is a major contributor to Nutlin-induced apoptosis in tumor cells

U. Moll, A. Vaseva, N. Marchenko, 2009, Cell cycle.

p73 suppresses polyploidy and aneuploidy in the absence of functional p53.

F. Talos, U. Moll, O. Petrenko, 2007, Molecular cell.

Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers.

V. Deleuze, D. Birnbaum, P. Vyas, 2020, Blood.

Risk for Sporadic Breast Cancer in Ataxia Telangiectasia Heterozygotes

U. Moll, 2001 .

Tissue-specific roles of p73 in development and homeostasis

U. Moll, A. Nemajerova, 2019, Journal of Cell Science.

Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors

U. Moll, A. Vaseva, N. Marchenko, 2011, Cell Death and Disease.

The Role of Ubiquitination in the Direct Mitochondrial Death Program of p53

U. Moll, N. Marchenko, Natasha D Marchenko, 2007, Cell cycle.

Inhibition of matrix metalloproteinase 9 activation by a specific monoclonal antibody.

U. Moll, J. Quigley, D. French, 1993, Hybridoma.

The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells

U. Moll, Shiv K. Singh, Ramona Schulz-Heddergott, 2021, Frontiers in Oncology.

Mutational analysis of p53 in human tumors: direct DNA sequencing and SSCP.

U. Moll, S. Erster, N. Slade, 2003, Methods in molecular biology.

p63 regulation by microRNAs

G. Blandino, U. Moll, 2009, Cell cycle.

Lack of defective expression of the ATM gene in sporadic breast cancer tissues and cell lines.

U. Moll, A. Zaika, A. Mateen, 2000, International journal of oncology.

p53Ψ is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state

Adrian Krainer, Scott W. Lowe, Matthew J. Lazzara, 2014, Proceedings of the National Academy of Sciences.

MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP.

T. Beißbarth, A. Levine, E. Markert, 2015, Molecular cell.

Tumor promoter-stimulated Mr 92,000 gelatinase secreted by normal and malignant human cells: isolation and characterization of the enzyme from HT1080 tumor cells.

U. Moll, J. Quigley, G. L. Youngleib, 1990, Cancer research.

Clostridium perfringens septicemia with massive hemolysis in a patient with Hodgkin's lymphoma.

A. Singer, U. Moll, P. Migdal, 1997, The American journal of emergency medicine.

Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.

M. Fraser, U. Moll, A. Basak, 2006, Cancer research.

Morphologic effects of neoadjuvant chemotherapy in locally advanced breast cancer.

U. Moll, J. Chumas, 1997, Pathology, research and practice.

Apoptotic cell death in disease—Current understanding of the NCCD 2023

S. Lipton, A. Ciechanover, T. Luedde, 2023, Cell Death & Differentiation.

Rb function is required for E1A-induced S-phase checkpoint activation

F. Talos, U. Moll, O. Petrenko, 2008, Cell Death and Differentiation.

Nuclear and mitochondrial apoptotic pathways of p 53

U. Moll, A. Zaika, 2001 .

p53 in autophagy control

W. Zong, U. Moll, 2008, Cell cycle.

Cortical hypoplasia and ventriculomegaly of p73‐deficient mice: Developmental and adult analysis

G. Meyer, F. Talos, U. Moll, 2014, The Journal of comparative neurology.

p73 is dispensable for commitment to neural stem cell fate, but is essential for neural stem cell maintenance and for blocking premature differentiation

F. Talos, U. Moll, E. Alexandrova, 2012, Cell Death and Differentiation.

Tissues and Cell Lines Gene in Breast Cancer p 73 Overexpression of the Wild Type Updated

U. Moll, A. Zaika, N. Marchenko, 1999 .

deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo.

U. Moll, A. Zaika, O. Petrenko, 2003, Molecular and cellular biology.

Statin as anti-cancer therapy in autochthonous T-lymphomas expressing stabilized gain-of-function mutant p53 proteins

U. Moll, A. Nemajerova, E. Di Cesare, 2020, Cell Death & Disease.

A biologically active parathyroid hormone-like substance secreted by an adenosquamous carcinoma of the transverse colon.

U. Moll, R. Zuna, M. Phillips, 1987, Human pathology.

Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target

U. Moll, Ramona Schulz-Heddergott, 2018, Cancers.

Malignant Human Cells: Isolation and Characterization of the Enzyme from HT1080 Tumor Cells1

U. Moll, J. Quigley, G. L. Youngleib, 1990 .

Immunoperoxidase Staining for Leu14 Antigen Identifies Thymic B Lymphocyte Follicular Hyperplasia in Myasthenia Gravis

F. Fromowitz, U. Moll, 1987 .

While p73 is essential, p63 is completely dispensable for the development of the central nervous system

F. Talos, U. Moll, M. Dobbelstein, 2011, Cell cycle.

Depleting stabilized GOF mutant p53 proteins by inhibiting molecular folding chaperones: a new promise in cancer therapy

U. Moll, E. Alexandrova, 2016, Cell Death and Differentiation.

Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis

U. Moll, N. Marchenko, W. Hanel, 2013, Cell Death and Differentiation.

UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib

T. Beißbarth, D. Proia, U. Moll, 2014, Cell Death and Disease.

Improving survival by exploiting tumor dependence on stabilized mutant p53 for treatment

D. Proia, G. Lozano, U. Moll, 2015, Nature.

SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

U. Moll, N. Marchenko, D. Li, 2011, Cell Death and Differentiation.

AD Award Number : DAMD 1798-1-8161 TITLE : Risk for Sporadic Breast Cancer in Ataxia Telangiectasia Heterozygotes

U. Moll, 2022 .

p53Ψ is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state

A. Krainer, S. Lowe, L. Cartegni, 2014, Proceedings of the National Academy of Sciences.

Targeting the heat shock protein 90: a rational way to inhibit macrophage migration inhibitory factor function in cancer

U. Moll, R. Schulz, 2014, Current opinion in oncology.